Nsomniyak Challenge:
CRY,,CryoLife, Inc., through its subsidiaries, engages in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries, as well as the development and commercialization of medical devices.
New product to control bleeding .Bio-foam could be a major hit.
FVE,, Long Term Care Facilities,,like the cash to debt levels.
VRS,,Verso Paper Co..Lot of competitors went Bk,High insider ownership,
TPI, Tianyin Pharmaceutical Co., Inc., through its subsidiary, Chengdu Tianyin Pharmaceutical Co., Ltd., engages in the development, manufacture, marketing, and sale of traditional Chinese medicines and other pharmaceuticals in the People’s Republic of China. It manufactures a portfolio of 34 products, as well as has a pipeline of 51 products, which are pending regulatory approvals with the China State Food and Drug Administration.This is my China play pays divy and will grow,,
QCOR,,biotech profitable,0 debt,,buying back shares..
We have also completed filing a supplemental New Drug Application (sNDA) for Acthar as a treatment for Infantile Spasms. There is currently no drug approved in the United States for the treatment of Infantile Spasms.
KKD,,My wild card,,Turnaround play ,Follow the fat people ,They know the easy way,,
